| Literature DB >> 12726864 |
Daniele Bergamaschi1, Milena Gasco, Louise Hiller, Alexandra Sullivan, Nelofer Syed, Giuseppe Trigiante, Isik Yulug, Marco Merlano, Gianmauro Numico, Alberto Comino, Marlene Attard, Olivier Reelfs, Barry Gusterson, Alexandra K Bell, Victoria Heath, Mahvash Tavassoli, Paul J Farrell, Paul Smith, Xin Lu, Tim Crook.
Abstract
Intact p73 function is shown to be an important determinant of cellular sensitivity to anticancer agents. Inhibition of p73 function by dominant-negative proteins or by mutant p53 abrogates apoptosis and cytotoxicity induced by these agents. A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers. Clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is influenced by this polymorphism, cancers expressing 72R mutants having lower response rates than those expressing 72P mutants. Polymorphism in p53 may influence individual responsiveness to cancer therapy.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12726864 DOI： 10.1016/s1535-6108(03)00079-5
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743